Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD).

Ambrodji, Alisa; Sadlon, Angélique; Amstutz, Ursula; Hoch, Dennis; Berger, Martin D.; Bastian, Sara; Offer, Steven M; Largiadèr, Carlo R. (2024). Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD). International journal of molecular sciences, 25(14) MDPI 10.3390/ijms25147599

[img]
Preview
Text
ijms-25-07599.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

Pre-treatment genotyping of four well-characterized toxicity risk-variants in the dihydropyrimidine dehydrogenase gene (DPYD) has been widely implemented in Europe to prevent serious adverse effects in cancer patients treated with fluoropyrimidines. Current genotyping practices are largely limited to selected commonly studied variants and are unable to determine phasing when more than one variant allele is detected. Recent evidence indicates that common DPYD variants modulate the functional impact of deleterious variants in a phase-dependent manner, where a cis- or a trans-configuration translates into different toxicity risks and dosing recommendations. DPYD is a large gene with 23 exons spanning nearly a mega-base of DNA, making it a challenging candidate for full-gene sequencing in the diagnostic setting. Herein, we present a time- and cost-efficient long-read sequencing approach for capturing the complete coding region of DPYD. We demonstrate that this method can reliably produce phased genotypes, overcoming a major limitation with current methods. This method was validated using 21 subjects, including two cancer patients, each of whom carried multiple DPYD variants. Genotype assignments showed complete concordance with conventional approaches. Furthermore, we demonstrate that the method is robust to technical challenges inherent in long-range sequencing of PCR products, including reference alignment bias and PCR chimerism.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

Graduate School:

Graduate School for Cellular and Biomedical Sciences (GCB)

UniBE Contributor:

Ambrodji, Alisa, Sadlon, Angélique, Amstutz, Ursula, Hoch, Dennis, Berger, Martin Dave, Largiadèr, Carlo Rodolfo

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1422-0067

Publisher:

MDPI

Language:

English

Submitter:

Pubmed Import

Date Deposited:

29 Jul 2024 09:31

Last Modified:

29 Jul 2024 09:41

Publisher DOI:

10.3390/ijms25147599

PubMed ID:

39062841

Uncontrolled Keywords:

DPYD Oxford Nanopore Technologies sequencing PCR chimera compound heterozygous fluoropyrimidines haplotype long-range amplicon pharmacogenomics rare variants

BORIS DOI:

10.48350/199323

URI:

https://boris.unibe.ch/id/eprint/199323

Actions (login required)

Edit item Edit item
Provide Feedback